ERBB2 and non-small cell lung carcinoma: Furthermore, in patients with metastatic NSCLC with HER2 mutation or HER2 amplification, the combination of pyrotinib and apatinib has exhibited favorable efficacy (mPFS 5.8-8.5 months) [132].